Immune-Cell-Based Therapy for COVID-19: Current Status

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiyuan, Liang, Qinghe, Chen, Fengsheng, Zheng, Jiehuang, Chen, Yan, Chen, Ziye, Li, Ruopeng, Li, Xiaojuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674523/
https://www.ncbi.nlm.nih.gov/pubmed/38005826
http://dx.doi.org/10.3390/v15112148
_version_ 1785140848133931008
author Wang, Yiyuan
Liang, Qinghe
Chen, Fengsheng
Zheng, Jiehuang
Chen, Yan
Chen, Ziye
Li, Ruopeng
Li, Xiaojuan
author_facet Wang, Yiyuan
Liang, Qinghe
Chen, Fengsheng
Zheng, Jiehuang
Chen, Yan
Chen, Ziye
Li, Ruopeng
Li, Xiaojuan
author_sort Wang, Yiyuan
collection PubMed
description Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.
format Online
Article
Text
id pubmed-10674523
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106745232023-10-25 Immune-Cell-Based Therapy for COVID-19: Current Status Wang, Yiyuan Liang, Qinghe Chen, Fengsheng Zheng, Jiehuang Chen, Yan Chen, Ziye Li, Ruopeng Li, Xiaojuan Viruses Review Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment. MDPI 2023-10-25 /pmc/articles/PMC10674523/ /pubmed/38005826 http://dx.doi.org/10.3390/v15112148 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Yiyuan
Liang, Qinghe
Chen, Fengsheng
Zheng, Jiehuang
Chen, Yan
Chen, Ziye
Li, Ruopeng
Li, Xiaojuan
Immune-Cell-Based Therapy for COVID-19: Current Status
title Immune-Cell-Based Therapy for COVID-19: Current Status
title_full Immune-Cell-Based Therapy for COVID-19: Current Status
title_fullStr Immune-Cell-Based Therapy for COVID-19: Current Status
title_full_unstemmed Immune-Cell-Based Therapy for COVID-19: Current Status
title_short Immune-Cell-Based Therapy for COVID-19: Current Status
title_sort immune-cell-based therapy for covid-19: current status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674523/
https://www.ncbi.nlm.nih.gov/pubmed/38005826
http://dx.doi.org/10.3390/v15112148
work_keys_str_mv AT wangyiyuan immunecellbasedtherapyforcovid19currentstatus
AT liangqinghe immunecellbasedtherapyforcovid19currentstatus
AT chenfengsheng immunecellbasedtherapyforcovid19currentstatus
AT zhengjiehuang immunecellbasedtherapyforcovid19currentstatus
AT chenyan immunecellbasedtherapyforcovid19currentstatus
AT chenziye immunecellbasedtherapyforcovid19currentstatus
AT liruopeng immunecellbasedtherapyforcovid19currentstatus
AT lixiaojuan immunecellbasedtherapyforcovid19currentstatus

Ejemplares similares